Person:
Gupta, Manoj

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Gupta

First Name

Manoj

Name

Gupta, Manoj
Author's Publications: search.filters.isAuthorOfPublication.15aad3a9-ed43-4622-a44f-7bb833c3e5de

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
    Fat on sale: role of adipose-derived stem cells as anti-fibrosis agent in regenerative medicine
    (BioMed Central, 2015) Gupta, Manoj; Ajay, Amrendra Kumar
    The potential use of stem cells for cell-based tissue repair and regeneration offers alternative therapeutic strategies for various diseases. Adipose-derived stem cells (ADSCs) have emerged as a promising source of stem cells suitable for transplantation in regenerative medicine and wound repair. A recent publication in Stem Cell Research & Therapy by Zhang and colleagues reports a new finding about the anti-fibrosis role of ADSCs and conditioned media derived from them on hypertrophic scar formation in vivo.
  • Thumbnail Image
    Publication
    Hearty miR-363 controls HAND1 in cardiac cell specification
    (BioMed Central, 2014) Gupta, Manoj; Rao, Tata Nageswara
    MicroRNAs regulate target gene expression post-transcriptionally in a myriad of cell types and play critical roles in diverse physiological and pathological processes, including cardiomyocyte development, differentiation, and regeneration. The recent publication in Stem Cell Research and Therapy by Wagh and colleagues reports a novel regulatory role for miR-363 in cardiomyocyte specification. By employing microRNA expression profiling and functional knockdown studies on human embryonic stem cell-derived cardiomyocytes, the authors identified miR-363 as an upstream negative regulator of left ventricular specification transcription factor HAND1.
  • Thumbnail Image
    Publication
    Dissecting diabetes/metabolic disease mechanisms using pluripotent stem cells and genome editing tools
    (Elsevier, 2015) Teo, Adrian Kee Keong; Gupta, Manoj; Doria, Alessandro; Kulkarni, Rohit
    Background: Diabetes and metabolic syndromes are chronic, devastating diseases with increasing prevalence. Human pluripotent stem cells are gaining popularity in their usage for human in vitro disease modeling. With recent rapid advances in genome editing tools, these cells can now be genetically manipulated with relative ease to study how genes and gene variants contribute to diabetes and metabolic syndromes. Scope of review We highlight the diabetes and metabolic genes and gene variants, which could potentially be studied, using two powerful technologies – human pluripotent stem cells (hPSCs) and genome editing tools – to aid the elucidation of yet elusive mechanisms underlying these complex diseases. Major conclusions hPSCs and the advancing genome editing tools appear to be a timely and potent combination for probing molecular mechanism(s) underlying diseases such as diabetes and metabolic syndromes. The knowledge gained from these hiPSC-based disease modeling studies can potentially be translated into the clinics by guiding clinicians on the appropriate type of medication to use for each condition based on the mechanism of action of the disease.
  • No Thumbnail Available
    Publication
    Preserved DNA Damage Checkpoint Pathway Protects against Complications in Long-Standing Type 1 Diabetes
    (Cell Press, 2015-08-04) Bhatt, Schweta; Gupta, Manoj; Khamaisi, Mogher; Martinez, Rachael; Gritsenko, MA; Wagner, Bridget K.; Guye, Patrick; Busskamp, Volker; Shirakawa, Jun; Wu, Gongxiong; Liew, CW; Clauss, Therese; Valdez, Ivan; El Ouaamari, Abdelfattah; Dirice, Ercument; Takatani, Tomozumi; Keenan, Hillary A.; Smith, RD; Church, George; Weiss, Ron; Wagers, Amy; Qian, Wei-Jun; King, George; Kulkarni, Rohit
    The mechanisms underlying the development of complications in type 1 diabetes (T1D) are poorly understood. Disease modeling of induced pluripotent stem cells (iPSCs) from patients with longstanding T1D(disease duration ≥ 50 years) with severe (Medalist +C) or absent to mild complications (Medalist −C) revealed impaired growth, reprogramming, and differentiation in Medalist +C. Genomics and proteomics analyses suggested differential regulation of DNA damage checkpoint proteins favoring protection from cellular apoptosis in Medalist −C. In silico analyses showed altered expression patterns of DNA damage checkpoint factors among the Medalist groups to be targets of miR200, whose expression was significantly elevated in Medalist +C serum. Notably, neurons differentiated from Medalist +C iPSCs exhibited enhanced susceptibility to genotoxic stress that worsened upon miR200 overexpression. Furthermore, knockdown of miR200 in Medalist +C fibroblasts and iPSCs rescued checkpoint protein expression and reduced DNA damage. We propose miR200-regulated DNA damage checkpoint pathway as a potential therapeutic target for treating complications of diabetes.